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Abstract 
Background:  Tyrosine kinase inhibitors (TKI) are the current 
standard therapy for patients with chronic myeloid leukemia 
(CML). Fluid retention and pleural effusions have been reported 
in patients treated with TKIs, particularly with dasatinib. Although 
TKIs have been shown to reverse pulmonary hypertension (PH) 
in animal models, there have been some reports of development 
of reversible PH with dasatinib. Methods:  We conducted a 
retrospective analysis on 401 patients diagnosed with CML in 
chronic phase (CP) who were treated with TKIs (imatinib, 
dasatinib, or nilotinib) as initial therapy for CML and had a 
transthoracic echocardiogram (TTE) done at some point during 
the course of therapy. PH was diagnosed if the patient had an 
estimated right ventricular systolic pressure (RVSP) of 35 mm Hg 
or greater. Secondary causes of PH (systolic or diastolic 
dysfunction on TTE, chronic obstructive pulmonary diseases 
[COPD], obstructive sleep apnea [OSA] and pulmonary 
embolism) were investigated during chart review. Results: 
Twenty (23%) out of 87 patients had evidence of PH by TTE; 
median age 57 years, with 46% being males. Six pts (30%) 
received nilotinib 400mg twice daily, 4 (20%) patients had 
imatinib (400mg; n=1, 600mg; n=1 and 800mg daily; n=2), and 10 
(50%) patients received dasatinib (dose varied 40-140mg daily). 
Five (25%) patients had coronary artery disease, 9 (45%) had 
systemic hypertension, 2 (10%) had COPD and 3 (15%) had 
OSA. Thirteen pts had serial TTE to compare the progression of 
PH including 6 (7%) who had a TTE prior to starting TKI. Among 
these 13 pts with serial TTE, 7 had rising RVSP with one patient 
having mild global hypokinesia, another with diastolic dysfunction 
and another with OSA. Four of those 7 patients had normal 
RVSP on their TTE prior to starting therapy. Six other pts had 
improvement in the RVSP on serial TTE, 4 of them with systemic 
hypertension. Two of those 6 patients had elevated RVSP on 
their TTE prior to starting therapy; one pt had no change. Eleven 
patients had pleural effusions (7 dasatinib, 3 imatinib, 1 nilotinib) 
associated with PH. Conclusions: TKI therapy is occasionally 
associated with development of PH, but RVSP may improve 
spontaneously in some patients. A prospective study is needed to 
further investigate the relationship between TKIs and the 
development of PH. 
Conclusions 
•  PH occurs in some patients with CML in 
chronic phase at baseline while in others it 
appears during therapy with TKI 
•  PH is seen less commonly in patients on 
imatinib compared to dasatinib or nilotinib. 
•  Concomitant pleural effusion and PH 
occurred more frequently in patients 
receiving dasatinib. 
•  Unclear whether there is a causal 
relationship between TKI and PH. 
•  A larger prospective study is needed to 
further investigate the relationship between 
TKIs and the development of PH. 
Background 
•  Pulmonary hypertension (PH) is characterized by 
elevated pulmonary artery pressure, right 
ventricular hypertrophy and, eventually, right 
ventricular failure. 
•  Unexplained PH has been described in some 
myeloproliferative disorders, however evidence is 
lacking in patients  with CML 1.  
•  There have been some reports on the occurrence 
of reversible PH after treatment with dasatinib2, 3. 
Objectives 
•  To investigate the frequency and characteristics of 
PH in patients with CML receiving therapy with 
tyrosine kinase inhibitors (TKIs). 
Disclosures 
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Patients and Methods 
•  Chart review of patients with CML treated with 
TKIs at MDACC between 2000 and 2009.  
•  Included patients with CML in chronic phase 
(CP) enrolled in several studies using imatinib 
(800 mg orally daily), nilotinib (400 mg BID) or 
dasatinib (100mg orally daily) as frontline 
therapy who had at least one trans-thoracic 
echocardiogram (TTE) done at baseline or 
during the course of therapy.  
•  Patients with CML CP who had received prior 
therapies were excluded. 
Table 2. TTE evidence of PH by 
therapy Table 1. Patient’s Characteristics  
Table 3. Incidence of pleural 
effusion 
Results 
•  Of 401 patients with CML treated with TKI as 
initial therapy, 87 had at least one TTE done  
•  Among 28 patients with pre-therapy (baseline) 
TTE, 8 (29%) patients had an elevated right 
ventricular systolic pressure (RVSP) at 
baseline. 
•  Elevated RVSP suggesting pulmonary 
hypertension during therapy occurred in 20 
(23%) of 87 patients. 
•  Elevated RVSP was seen most commonly in 
patients treated with dasatinib (occurring in 10 
of 19 patients [53%]) [mean 36 mmHg, range 
35-50 mmHg] and nilotinib (seen on 6 of 14 
patients [43%]) [mean 36 mmHg, range 31-50 
mmHg] (Table 2).  
•  LVEF remained normal in 18 (90%) of the 20 
patients with elevated RVSP, suggesting that 
PH could possibly be related to the use of TKIs. 
•  70% of patients with elevated RVSP while on 
therapy with dasatinib had evidence of 
concomitant pleural effusions.  
•  Only 4 of 54 (8%) patients treated with imatinib 
had evidence of elevated RVSP (2 had other 
possible etiologies). 
References:
1.  Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. 
Unexplained pulmonary hypertension in chronic 
myeloproliferative disorders. Chest 2001;120:801-8. 
2.  Rasheed W, Flaim B, Seymour JF. Reversible severe 
pulmonary hypertension secondary to dasatinib in a 
patient with chronic myeloid leukemia. Leuk Res 
2009;33:861-4. 
3.  Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, 
Gallamini A. Reversible dasatinib-induced pulmonary 
arterial hypertension and right ventricle failure in a 
previously allografted CML patient. Bone Marrow 
Transplant 2009;43:967-8. 
4.  Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural 
effusion in patients with chronic myelogenous leukemia 
treated with dasatinib after imatinib failure. J Clin Oncol 
2007;25:3908-14. 
Contact Details: 
Jorge Cortes, M.D. 
Department of Leukemia 
University of Texas, M.D. 
Anderson Cancer Center 
1515 Holcombe Blvd, Unit 428 
Houston, TX  77030 
(713) 794-5783 – phone        
(713) 794-4297 – fax  





after therapy (one 
had elevated RVSP 
at baseline) 
(1 dasatinib, 1 






No pre-TKI TTE 
available 
6 
Pre-TKI TTE available 




while on therapy 
(Dasatinib: 2 
Stopped , 1 dose 
reduced by 50% 
Nilotinib: 1 stopped) 
3 
RVSP worsened or 
stable while on 
therapy 
(1 dasatinib, 1 
imatinib, 1 nilotinib) 
Median (range) N° (%) 
Age (y) 56 (30-82) 
Males 11 (55) 
Median follow-up (months) 16 (2-54) 17 (51) 
Median WBC (x109/L) 27.2 (2.7- 
156.5) 
Platelets (x109/L) 228 (70-599) 
Hemoglobin (g/dl) 12.2 (6.2-14.1) 
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TKI, tyrosine kinase inhibitor; TTT, transthoracic echocardiogram; RVSP, 
right ventricle systolic pressure; CAD, coronary artery disease; EF ejection 
fraction; COPD, chronic obstructive pulmonary disease. 
Results 
•  Of the patients that had elevated RVSP (suggesting 
PH), 13 patients had serial TTE during therapy 
(figure 1).  
•  7 patients experienced worsening PH (receiving 
Dasatinib n=2, Imatinib n=2, Nilotinib n= 3) 
•  4 had resolution (receiving imatinib n=2, 
dasatinib n=3, nilotinib n=1) while on therapy. 
The improvement in RVSP was seen after 
switching from the TKI to another agent 
(Dasatinib n=2, nilotinib n=1) or reducing the 
dose of dasatinib by 50% (N=1). 
•  2 of 3 patients with elevated RVSP at baseline 
normalized after starting therapy with nilotinib. 
•  Pleural effusion was identified in 11 patients (55%) 
with elevated RVSP (Table 3). 
•  Pleural effusion occurred most frequently among 
patients on dasatinib (70%). 










Imatinib 3 of 4 (75%) 1 
Dasatinib 7 of 10 (70%) 4 
Nilotinib 1 of 6 (17%) 0 
TKI, tyrosine kinase inhibitor; RSVP, right ventricle systolic 
pressure, PE=  Pleural Effusion 
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